LongBio Pharma (Suzhou) Co., Ltd. (HKG:1779)
Hong Kong · Delayed Price · Currency is HKD 110.30
-4.00 (-3.50%)
Sep 10, 2026, 1:14 PM HKT
LongBio Pharma (Suzhou) Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 903.76 | 95.05 | 66.62 | 117.23 |
Trading Asset Securities | 15.07 | 95.21 | 40.1 | - |
Cash & Short-Term Investments | 1,223 | 190.26 | 106.72 | 117.23 |
Cash Growth | - | 78.28% | -8.96% | - |
Other Receivables | - | 1.1 | 0.06 | 3.65 |
Receivables | - | 1.1 | 0.06 | 3.65 |
Restricted Cash | 2.29 | 0.88 | - | - |
Other Current Assets | 10.21 | 9.83 | 16.62 | 4.45 |
Total Current Assets | 1,236 | 202.07 | 123.4 | 125.32 |
Property, Plant & Equipment | 21.31 | 13.04 | 18.14 | 19.13 |
Other Long-Term Assets | 17.04 | 12.44 | 7.37 | 1.02 |
Total Assets | 1,274 | 227.56 | 148.91 | 145.48 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 23.69 | 5.72 | 12.76 | 5.33 |
Accrued Expenses | 51.57 | 32.27 | 12.06 | 13.21 |
Short-Term Debt | 45 | 35 | 37.88 | 13 |
Current Portion of Long-Term Debt | - | - | 23.64 | 22.43 |
Current Portion of Leases | 3.77 | 2.13 | 4.11 | 3.62 |
Current Income Taxes Payable | - | - | - | 0.04 |
Current Unearned Revenue | 2.38 | 0.56 | 2.04 | - |
Other Current Liabilities | 11.65 | 7.78 | 2.25 | 3.52 |
Total Current Liabilities | 138.05 | 83.45 | 94.73 | 61.15 |
Long-Term Debt | - | - | 379.13 | 270.47 |
Long-Term Leases | 7.56 | 0.79 | 2.92 | 5.51 |
Long-Term Unearned Revenue | 1.22 | 2.8 | 2.41 | 2.04 |
Total Liabilities | 146.84 | 87.04 | 479.19 | 339.16 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 74.19 | 60 | 7.99 | 7.66 |
Additional Paid-In Capital | - | 181.08 | 294.71 | - |
Retained Earnings | - | -110.89 | -336.77 | -199.45 |
Comprehensive Income & Other | 1,053 | 10.32 | -296.22 | -1.9 |
Shareholders' Equity | 1,127 | 140.52 | -330.28 | -193.69 |
Total Liabilities & Equity | 1,274 | 227.56 | 148.91 | 145.48 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 56.33 | 37.92 | 447.68 | 315.03 |
Net Cash (Debt) | 1,167 | 152.34 | -340.96 | -197.81 |
Net Cash Growth | - | - | - | - |
Net Cash Per Share | 18.91 | 2.69 | -7.18 | -4.62 |
Filing Date Shares Outstanding | 61.97 | 74.19 | 48.48 | 42.8 |
Total Common Shares Outstanding | 61.97 | 60 | 48.48 | 42.8 |
Working Capital | 1,098 | 118.62 | 28.67 | 64.18 |
Book Value Per Share | 18.19 | 2.34 | -6.81 | -4.53 |
Tangible Book Value | 1,127 | 140.52 | -330.28 | -193.69 |
Tangible Book Value Per Share | 18.19 | 2.34 | -6.81 | -4.53 |
Machinery | - | 20.14 | 18.46 | 17.89 |
Construction In Progress | - | - | - | 5.01 |
Leasehold Improvements | - | 9.64 | 8.81 | - |